FDA grants accelerated approval to camizestrant for ESR1-mutated advanced breast cancer.
- FDA
- camizestrant
- AstraZeneca
fda.gov
Kalshi
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?36¢to97¢
Markets
PriceMoveHead startNowReports
- 0sFirstfda.gov
- +6m 26sRepeatedLiveSquawk on X
- +11mRepeatedFirst Squawk on X
- +23m36¢to97¢
- +27mNew detailU.S. Food and Drug Administration
- +3h 36mOfficialAstraZeneca US press release on astrazen
- +3dOfficialAstraZeneca's filing on SEC EDGAR